Cargando…

JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling

Overactive Janus kinases (JAKs) are known to drive leukemia, making them well-suited targets for treatment. We sought to identify new JAK-activating mutations and instead found a JAK1-inactivating pseudokinase mutation, V666G. In contrast to other pseudokinase mutations that canonically lead to an a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grant, Alice H., Rodriguez, Alejandro C., Rodriguez Moncivais, Omar J., Sun, Shengjie, Li, Lin, Mohl, Jonathon E., Leung, Ming-Ying, Kirken, Robert A., Rodriguez, Georgialina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095075/ https://www.ncbi.nlm.nih.gov/pubmed/37047778 http://dx.doi.org/10.3390/ijms24076805

Ejemplares similares

Phosphorylation of Tyrosine 841 Plays a Significant Role in JAK3 Activation
por: Sun, Shengjie, et al.
Publicado: (2023)

The Many Faces of JAKs and STATs Within the COVID-19 Storm
por: Grant, Alice H., et al.
Publicado: (2021)

Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain
por: Raivola, Juuli, et al.
Publicado: (2018)

JAK3 Y841 Autophosphorylation Is Critical for STAT5B Activation, Kinase Domain Stability and Dimer Formation
por: Rodriguez, Georgialina, et al.
Publicado: (2023)

Crystal structures of the Jak2 pseudokinase domain and the pathogenic mutant V617F
por: Bandaranayake, Rajintha M., et al.
Publicado: (2012)

Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling
por: Raivola, Juuli, et al.
Publicado: (2019)

Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies
por: Rodriguez Moncivais, Omar J., et al.
Publicado: (2023)

Quadruple and Truncated MEK3 Mutants Identified from Acute Lymphoblastic Leukemia Promote Degradation and Enhance Proliferation
por: Ayala-Marin, Yoshira M., et al.
Publicado: (2021)

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain
por: Virtanen, Anniina T., et al.
Publicado: (2023)

Structure of a pseudokinase domain switch that controls oncogenic activation of Jak kinases
por: Toms, Angela V., et al.
Publicado: (2013)

The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border
por: Grant, Alice Hernandez, et al.
Publicado: (2021)

Phosphorylation of CrkL S114 induced by common gamma chain cytokines and T-cell receptor signal transduction
por: Estrada, Armando, et al.
Publicado: (2021)

Rapid Shift from SARS-CoV-2 Delta to Omicron Sub-Variants within a Dynamic Southern U.S. Borderplex
por: Robles-Escajeda, Elisa, et al.
Publicado: (2023)

Ab Initio Modeling and Experimental Assessment of Janus Kinase 2 (JAK2) Kinase-Pseudokinase Complex Structure
por: Wan, Xiaobo, et al.
Publicado: (2013)

The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling
por: Tactacan, Carole M., et al.
Publicado: (2015)

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
por: Kim, Sang-Kyu, et al.
Publicado: (2018)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Genome Wide Mapping Reveals PDE4B as an IL-2 Induced STAT5 Target Gene in Activated Human PBMCs and Lymphoid Cancer Cells
por: Nagy, Zsuzsanna S., et al.
Publicado: (2013)

Correction: Genome Wide Mapping Reveals PDE4B as an IL-2 Induced STAT5 Target Gene in Activated Human PBMCs and Lymphoid Cancer Cells
por: Nagy, Zsuzsanna S., et al.
Publicado: (2013)

Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction
por: Liu, Chun-Shan, et al.
Publicado: (2017)

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
por: Ashami, Kidist, et al.
Publicado: (2018)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors
por: Dusa, Alexandra, et al.
Publicado: (2010)

Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy
por: Koppikar, Priya, et al.
Publicado: (2012)

Progenitor expansion in apc mutants is mediated by Jak/Stat signaling
por: Lin, Junji, et al.
Publicado: (2011)

ROCKing the JAKs
por: Peelman, Frank, et al.
Publicado: (2013)

The Jak Tree
Publicado: (1889)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Alternative ways of modulating JAK-STAT pathway: Looking beyond phosphorylation
por: Timofeeva, Olga A., et al.
Publicado: (2012)

Jak2-mediated phosphorylation of Atoh1 is critical for medulloblastoma growth
por: Klisch, Tiemo J, et al.
Publicado: (2017)

IL-6/JAK2-dependent G6PD phosphorylation promotes nucleotide synthesis and supports tumor growth
por: Qiu, Xuemei, et al.
Publicado: (2023)

Inhibition of JAK3 with a novel, selective, and orally active small molecule induces therapeutic response in T-cell malignancies
por: Ross, Jeremy A., et al.
Publicado: (2013)

TNFα Mediated IL-6 Secretion Is Regulated by JAK/STAT Pathway but Not by MEK Phosphorylation and AKT Phosphorylation in U266 Multiple Myeloma Cells
por: Lee, Chansu, et al.
Publicado: (2013)

Phosphorylation-dependent pseudokinase domain dimerization drives full-length MLKL oligomerization
por: Meng, Yanxiang, et al.
Publicado: (2023)

What is the point of pseudokinases?
por: Raju, Saravanan, et al.
Publicado: (2015)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ci199uvdl98bll1i9ti38l6k1r